ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. Nov 26 special report | November 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Pasche Named Director of Wake Forest Cancer Center

March 7, 2014

Funding opportunities listed.

February 20, 2004

ODAC Oks Carboplatin As 1st Line Ovarian Therapy; Other Drugs

July 12, 1991

In Brief: Ways & Means Shakeup Means More Liberal Health Insurance Bill; OMB’s Nutty Rational For Cuts

December 20, 1974

NIH Recovery Act Announcements

March 27, 2009

Cancer Panel: Lack Of Genetic Basis For Race Presents Dilemma For Studies; Data Collection Must Include Socioeconomic Measures, Report To Clinton Says

March 20, 1998